Christine Koch, Markus Göller, Eckart Schott, Oliver Waidmann, Mark op den Winkel, Philipp Marius Paprottka, Stephan Zangos, Thomas Vogel, Wolf Otto Bechstein, Stefan Zeuzem, Frank Thomas Kolligs, Jörg Trojan
- Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
MetadatenVerfasserangaben: | Christine KochORCiD, Markus Göller, Eckart SchottGND, Oliver WaidmannORCiDGND, Mark op den Winkel, Philipp Marius Paprottka, Stephan ZangosGND, Thomas Vogel, Wolf Otto BechsteinORCiDGND, Stefan ZeuzemORCiDGND, Frank Thomas Kolligs, Jörg TrojanORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-624367 |
---|
DOI: | https://doi.org/10.3390/cancers13092121 |
---|
ISSN: | 2072-6694 |
---|
Titel des übergeordneten Werkes (Englisch): | Cancers |
---|
Verlag: | MDPI |
---|
Verlagsort: | Basel |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 28.04.2021 |
---|
Datum der Erstveröffentlichung: | 28.04.2021 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 06.09.2021 |
---|
Freies Schlagwort / Tag: | HCC; TACE; sorafenib; treatment |
---|
Jahrgang: | 13 |
---|
Ausgabe / Heft: | 9, art. 2121 |
---|
Seitenzahl: | 11 |
---|
Erste Seite: | 1 |
---|
Letzte Seite: | 11 |
---|
HeBIS-PPN: | 487476336 |
---|
Institute: | Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Open-Access-Publikationsfonds: | Medizin |
---|
Lizenz (Deutsch): | Creative Commons - Namensnennung 4.0 |
---|